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     Chronic kidney disease (CKD) is probably the most important problem of public health in advanced 
countries. Kidneys are often damaged as a result of high blood pressure. One of our main concerns in 
patients with hypertension is early detection of kidney disorders. The routine biomarkers such as creatinine 
have some limitation for this purpose, however recent studies suggest plasma NGAL to be a better marker. 
Therefor in this study we assessed the diagnostic value of plasma NGAL and compared it with serum 
creatinine in hypertensive patients. This study was performed on 42 hypertensive patients and 30 healthy 
Volunteer, both with normal serum creatinine and urea concentration  who referred to Shohada Tajrish 
Hospital, plasma NGAL were measured subsequently using ELISA method and eGFR was considered  as 
the gold standard method(cut off value of<78ml.min.1.73m
2
). mean NGAL level was significantly higher 
in patients  in comparison to control group. The sensitivity and specificity were  96% and 100% 
respectively for plasma NGAL(≥32.2 ng/ml) compared with 76% and 47% for serum creatinine (>0.97 
mg/dl). Our findings indicate that NGAL is a better indicator of kidney impairment in the early stages of 
CKD as compared with serum creatinine in hypertensive patients. 
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INTRODUCTION     
Chronic kidney disease (CKD), is determined by 
a condition with progressive loss of the ability of 
the kidneys to maintain normal levels of protein 
metabolism products (such as urea), water 
balance and maintain normal blood pressure and 
hematocrit, electrolytes, and body's acid-base. 
Based on the definitions, chronic kidney disease, 
is defined as structural or functional damage of 
the kidney, lasting for more than three 
months[1]. Typically, diabetes (97%) and 
hypertension (95%) are  risk factors for chronic 
kidney disease[2] . About 25% of adults 
worldwide have hypertension (systolic blood 
pressure ≥ 140mmHg or diastolic blood 
pressure≥90mmHg which is confirmed by a 
doctor at least in two separate occasions.  ), high 
blood pressure is a pathological  factor  of  
decreased kidney function [3, 4]. Over the past 
twenty years it has been learned that earlier 
identification and treatment of kidney disease can 
result in preventing kidney disease progression. 
Thus, a biomarker of kidney damage that is able 
to indicate the presence of both early damage and 
identify patients at an increased risk of 
progressive disease would impact kidney disease 
diagnosis and treatment. Although blood 
creatinine is commonly used as an index of renal 
function, creatininemia is primarily a marker of 
glomerular  filtration and cannot be considered 
an ideal biomarker for the estimation of kidney 
injury, because it is insensitive and is influenced 
by muscle mass, gender, race, and medications 
and is  unreliable to diagnose renal tubular injury 
in the absence of significant reduction in the 
glomerular filtration rate (GFR)[5, 6]. The main 
cause that CKD is dangerous, is inability to 
detect it in its early stages by a routine marker 
such as creatinine; Finally, the disease can be 
treated if detected at an early stage. Neutrophil 
Gelatinase-Associated Lipocalin( NGAL)  has 
recently been proved useful to quantitate CKD[7] 
and it has the potential to be an ideal biomarker 
in early detection of CKD. NGAL is a small 25-
kD molecule,  which belongs to the lipocalin 
family of proteins [8]; NGAL interacts on the 
 




cell membrane with specific  receptors (24p3R 
and megalin) as a complex with iron-
siderophores (Holo-NGAL) or alone (Apo-
NGAL). After internalization, Holo-NGAL is 
able to release the iron it carried into the 
cytoplasm, leading to iron accumulation and 
regulating specific iron-dependent gene 
pathways. Endosomal NGAL captures iron via a 
hypothetical intracellular siderophore, which is 
followed by recycling to the extracellular space. 
NGAL then may be destroyed within the cell or 
recycled outside as Apo-NGAL. Most protective 
effects attributed to this protein probably are 
realized through mechanisms based on iron-
dependent gene regulation. Moreover, Apo-
NGAL can capture intracellular iron-
siderophores and transport these to the 
extracellular space, thus depriving the cell of its 
iron reserves. This probably represents the way 
NGAL exerts strong antibacterial properties and 
under particular conditions may promote cellular 
apoptosis. NGAL seems to have more complex 
activities than just its antimicrobial effect; 
Induction of NGAL may limit tubular injury by 
modulating various cellular responses, such as 
proliferation, apoptosis, and differentiation, but 
the specific mechanisms for such an action are 
not well understood  yet [9]. massively released 
from renal tubular cells after various injuring 
stimuli  [10].The main aim of  the present study 
was to examine the eventual predictive value of 
plasma NGAL measurement for detecting CKD 
in adult patients with high blood pressure, in 
comparision with serum creatinine.  
 
MATERIALS AND METHODS     
     The study  was performed on 42 hypertensive 
patient,  that their blood pressure is not well 
controlled, (systolic blood pressure ≥ 140mmHg 
or diastolic blood pressure≥90mmHg) mean age 
of 54.33±8.9 years ,who referred to Shohada 
Tajrish Hospital and 30 healthy (14 men and 16 
women) volunteers  mean age 54.7±6.8. To 
minimize potential confounding factors, patients 
with chronic disease such as diabetes, liver, 
cardiovascular disease and elevated serum 
creatinine and urea were excluded from the 
study. Patients history was carefully recorded by 
interview and confirmed by checking patients 
record, also recording drug prescription. Clinical 
examination, including assessment of blood 
glucose, was performed. BP was measured by a 
doctor at least at two separate occasions and the 
average value was considered for data analysis. 
Blood samples were taken in the morning before 
any food intake. Biochemical parameters 
including urea, creatinine were measured 
according to the standard methods in the routine 
clinical laboratory. eGFR was assessed using 




For NGAL measurement blood was placed into 
chilled vacutainer tubes containing potassium 
ethylenediamine tetracetate (EDTA) and the 
plasma was promptly separated by a refrigerated 
centrifuge (at 4c,5min,5000rpm) and the samples 
were stored at -20 c until assessment time. 
NGAL was evaluated using commercially 
available ELISA kit (Biovender,Norway). 
Statistical analysis  
  Data were expressed as mean±SD or %. T-test 
was used for comparison of the means between 
two groups. To assess correlation between eGFR  
and other variables Pearson coefficient was 
performed. Receiver operating characteristics 
(ROC) analysis was used to calculate the area 
under the curve for NGAL and  sCr to find the 
best pNGAL, cut-off values for identifying the 
patient with risk factor for CKD. All results were 
considered significant if P value was <0.05. Data 
were analyzed using SPSS software version 18. 
 
RESULTS 
   This study was performed on 42 high blood 
pressure patients (10men and 32 women) mean 
age 54.33±8.89 and 30 healthy individuals (14 
men and 16 women) mean age 54.7±6.8. As 
shown in table 1 the plasma NGAL level, 
creatinine and eGFR were significantly higher in 
patients compared to the control group. 
 
Table1. Comparision of the mean serum creatinine , eGFR and NGAL in the patient and control group. 
Variables Patient Control Group P-Value 
 n=42 n=3  
<0.001 124.54±118.67) )(14.59±3.71) NGAL 
0.036 (1.058±0.18) 0.97±0.136) )Cr 
0.001 (77.73±20.19) (90.74±10.38) eGFR(ml/min/1.73m²) 
 




In this study, using the Pearson correlation 
coefficient, eGFR correlation with various 
parameters including plasma NGAL and sCr 
were measured; Based on the results from the 
above parameters, eGFR showed significant 
inverse correlation with NGAL (R = - .593, P 
<0.001), and creatinine (R = - .251, P = .033 ). 
ROC analysis (Fig1) showed  an area under the 
curve( AUC) for sCr and pNGAL of 0.63(95% 
CI, 0.50 to 0.76) and 0.92(95% CI, 0.87 to 0.98) 
respectively. pNGAL area was significantly 
different with respect tothat of Cr . The best cut-
off values to predict early stages of kidney 
disease  for plasma NGAL was found to be 
≥32.2 ng/ml ( sensitivity and specificity were 
96% and 100% respectively )whereas for sCr  it 
was>0.97 mg/dl ( sensitivity 76% and 
specificity 47% ).As shown in Fig 1, percent 
under the ROC curve for NGAL is greater than 
creatinine  and it is 99%. 
 
 
Figure 1. Receiver operating characteristics curves of 
serum creatinin(sCr),plasma neutrophil gelatinase-
associated lipocalin (pNGAL), considering for early 
detection  of CKD as status variable. The area under the 
curve for sCr, pNGAL  0.63(95% CI, 0.50 to 0.76), 
0.92(95% CI, 0.87 to 0.98), respectively. pNGAL was 
areas significantly different than that of sCr (P <0.001). 
The best cut-off values to predict early stage were 
determined. For pNGAL this value was found to be 32.2 




    Early detection and treatment of kidney 
disease can result in preventing kidney 
disease progression. Thus, an early biomarker 
of kidney damage which can identify patients 
at an increased risk of progressive disease 
would impact kidney disease diagnosis and 
treatment[11].  
Since creatinine is not a sensitive marker of 
kidney function and since eGFR also has 
some limitations, there is a growing need to 
find an early marker of kidney damage ,new 
studies suggest that NGAl  has the potential to 
be an ideal biomarker to find early kidney 
damage in patients at risk [11]. NGAL is 
synthesized systemically in response to  
kidney damage. It could be also produced 
locally by injured tubules. A third source of 
NGAL may be activated 
neutrophils/macrophages or inflamed 
vasculature, frequently found in CKD [12]. In 
our study we assessed whether NGAL 
represented a novel, sensitive biomarker of 
kidney function.  We found that mean plasma 
NGAL level was significantly higher in 
hypertensive patients compared with the 
control group this result in consistent with the 
observation of David Bolignano et al who 
reported higher mean sNGAL in patients with 
CKD  compared with the healthy control 
group [13].  
Furthermore in this study eGFR showed 
significant inverse correlation with NGAL (R 
= - .593, P <0.001), and creatinine (R = - 
.251, P = .033 ), in the patients. Where as  
pNGAL inverse correlation with eGFR 
displayed higher values compared with sCr. 
Similar results were observed on univariated 
analysis by David Bolignano et al that showed 
significant inverse correlation between eGFR 
and sNGAL(r=-0.44, P= 0.0001)[13]. In our 
study, we confirmed finding by Mitsnefes et 
al. who showed  that NGAL could represent a 
marker of renal function in children with 
CKD(7). In David B et al research the area 
under the curve for eGFR and sNGAL was 
0.64 (95% CI, 0.53 to 0.73) and 0.70 (95% 
CI, 0.60 to 0.79) respectively.  SNGAL area 
was statistically different with respect to that 
of eGFR(P < 0.03). In our study ROC 
analysis  indicated that NGAL was a better 
indicator than sCr for predicting a GFR<78 
ml/min.   
In our study the best cut-off values to predict 
early stage were determined. For pNGAL this 
value was found to be 32.2 ng/ml, with a 
sensitivity of  96%  and a specificity of 100%. 
In David Bolignano et al the best cut-off level 
for sNGAL was found to be 435 ng/ml 
 




(sensitivity 83.9%, specificity 53.8%)(13)  .In 
this study Cut-off values are much lower in 
contrast with previous studies probably 
because  patients in our study are at early  
stages of CKD. In our subjects, the best  
overall agreement with eGFR was found for 
serum NGAL. Moreover, our data suggest 
that NGAL assay is also able to detect 
patients with only subclinical or modest renal 
damage, which may be not revealed by 
significant variations in renal function test, 
such as serum creatinine or GFR.  
 
CONCLUSION 
    Our results indicate that NGAL is a better 
indicator of kidney impairment in the early 
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